Stay updated on IDO Inhibitor with Checkpoint Inhibitors for Melanoma Clinical Trial
Sign up to get notified when there's something new on the IDO Inhibitor with Checkpoint Inhibitors for Melanoma Clinical Trial page.

Latest updates to the IDO Inhibitor with Checkpoint Inhibitors for Melanoma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedRevision: v3.4.2 was added; the government funding status notice and Revision: v3.4.1 were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check21 days agoChange DetectedA site-wide notice about a lapse in government funding and open status was added with a link for status updates; the page shows a Revision: v3.4.1, replacing the previous v3.4.0.SummaryDifference0.4%

- Check28 days agoChange DetectedThe changes are minor UI/text updates on the study page, including showing the glossary, updating the 'Last Update Submitted that Met QC Criteria' label, removing 'No FEAR Act data' wording, and adding a 'Revision: v3.4.0' note. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision: v3.3.4 was added to the page; this is a minor UI/version update with no impact on study data or functionality; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedAdded Georgia, Iowa, Minnesota, New Mexico, Pennsylvania, and Utah locations and updated the record revision to v3.3.3; previous location entries from v3.3.2 were removed.SummaryDifference0.7%

- Check91 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2. No substantive changes to study details or page content are evident.SummaryDifference0.1%

Stay in the know with updates to IDO Inhibitor with Checkpoint Inhibitors for Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IDO Inhibitor with Checkpoint Inhibitors for Melanoma Clinical Trial page.